Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epigallocatechin gallate-based cancer therapeutic - Amplexd Therapeutics

Next Previous
Drug Profile

Epigallocatechin gallate-based cancer therapeutic - Amplexd Therapeutics

Alternative Names: Epigallocatechin gallate non-invasive topical therapy - Amplexd Therapeutics

Latest Information Update: 28 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amplexd Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Catechins; Chemopreventatives; Flavonoids; Herbal medicines
  • Mechanism of Action Apoptosis stimulants; Cell cycle inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cervical intraepithelial neoplasia

Most Recent Events

  • 20 May 2024 Preclinical trials in Cervical intraepithelial neoplasia in USA (Vaginal) before May 2024
  • 20 May 2024 Amplexd Therapeutics announces intention to submit IND for Cervical intraepithelial neoplasia in 2024
  • 20 May 2024 Amplexd Therapeutics plans a phase I/II trial for Cervical intraepithelial neoplasia (Vaginal, Suppository) in 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top